Clinical Trials Logo

Clinical Trial Summary

Aim of the study: 1- Detect common types of familial dyslipidemia. 2- Significance and relationship between Epicardial fat thickness and familial dyslipidemia.


Clinical Trial Description

Dyslipidemias or dyslipoproteinemias are quantitative changes in total cholesterol concentration, respective fractions, or triglycerides in the plasma. Lipids, such as cholesterol or triglycerides, are absorbed from the intestines and are carried throughout the body via lipoproteins for energy, steroid production, or bile acid formation . Major contributors to these pathways are cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and high-density lipoprotein (HDL). An imbalance of any of these factors, either from organic or nonorganic causes, can lead to dyslipidemia. Dyslipidemias can result from primary lipoprotein metabolism changes due to different genetic causes (primary dyslipidemias) or as a consequence of exogenous factors or other pathologies (secondary dyslipidemias). Primary dyslipidemia can be due to familial disorders as well. Autosomal dominant mutations cause most cases of familial hypercholesterolemia in LDL receptors, which causes an elevation in LDL-C levels. Other mutations in the cholesterol pathway have been identified but are less common. Several health behaviors can have effects and increase lipid levels. Examples include tobacco use, physical inactivity, nutrition, and obesity. Specifically, nutrition risk factors include the insufficient consumption of fruits, nuts/seeds, vegetables, or high consumption of saturated fats. The heart and vessels are surrounded by layers of adipose tissue, which is a complex organ composed of adipocytes, stromal cells, macrophages, and a neuronal network, all nourished by a rich microcirculation . The layers of adipose tissue surrounding the heart can be subdivided into intra- and extrapericardial fat. Their thicknesses and volumes can be quantified by echocardiography and CT or magnetic resonance imaging, respectively. The term extrapericardial fat defines thoracic adipose tissue external to the parietal pericardium. It originates from primitive thoracic mesenchymal cells and thus derives its blood supply from noncoronary sources. Intrapericardial fat is further subdivided into epicardial and pericardial fat. Anatomically, Epicardial and pericardial adipose tissues are clearly different. Epicardial fat is located between the outer wall of the myocardium and the visceral layer of pericardium. Epicardial adipose tissue (EAT) is a component of visceral adiposity and mediates cardiac function and atherosclerosis via expression of several bioactive molecules. EAT is a measure of the adipose tissue between the myocardium and visceral pericardium which can be visualized using transthoracic echocardiogram as a non-invasive assessment of EAT. Some studies have used EAT as a marker for metabolic syndrome; however, it does not have standard utility related to other cardiac syndromes. This fat layer buffers the coronary arteries from cardiac contraction and arterial pulse wave while providing the myocardium with necessary substrate through diffusion of free fatty acids. 4 When there is a surplus of energy, free fatty acids are readily converted into triglycerides and stored in epicardial adipocytes, increasing the volume of the epicardial adipose layer and serving as a triglyceride depot for the myocardium to draw from during periods of higher energy needs. Studies in adults suggest that increased EAT results in greater cytokine production in the fat directly surrounding the coronary vessels, including tumor necrosis factor-αas well as several interleukins. These cytokines contribute to atherosclerosis by increasing lipolysis, increasing inflammation, and causing endothelial dysfunction. Endothelial dysfunction coupled with migration of macrophages, basophils, and other cells further exacerbate plaque formation and eventually causes disruption in the structure of the intima and flow within the lumen.8,9Recent studies suggest that increased EAT is predictive of incident CVD in adults with T1D independent of traditional CVD risk factors such as BMI. Although the majority of studies examining EAT have been conducted in the adult population, EAT has been measured in pediatric studies of obesity and metabolic syndrome. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06101771
Study type Observational
Source Assiut University
Contact mina mamdoh Tadros, resident doctor
Phone +201286186279
Email do7a.mmdoh@gmail.com
Status Not yet recruiting
Phase
Start date December 20, 2023
Completion date December 30, 2025

See also
  Status Clinical Trial Phase
Completed NCT00001154 - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT02837367 - Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People N/A
Active, not recruiting NCT02600338 - Meta-analyses of the Effect of Legumes on Blood Pressure N/A
Active, not recruiting NCT02223793 - Vascular Lifestyle-Intervention and Screening in Pharmacy N/A
Completed NCT02163044 - The Hellenic Postprandial Lipemia Study (HPLS)
Recruiting NCT01972113 - Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study) N/A
Recruiting NCT01705873 - Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen N/A
Completed NCT01764295 - Clinical Study for Patients With Hypertension Associated With Dyslipidemia Phase 3
Completed NCT01531062 - Effect of Nigella Sativa on Lipid Profiles in Elderly Phase 2
Completed NCT01990391 - Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities N/A
Terminated NCT01414166 - Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108) Phase 3
Recruiting NCT01670968 - HIV Reverse Cholesterol Transport Study
Completed NCT00977288 - A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029) Phase 2
Completed NCT01285544 - The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia Phase 4
Withdrawn NCT00664287 - Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082) Phase 3
Completed NCT00768274 - Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol Phase 1/Phase 2
Completed NCT01483235 - Reduced Cardiac Rehabilitation Program N/A
Completed NCT00300430 - Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. Phase 3
Completed NCT00309738 - Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin Phase 3